| Literature DB >> 29529048 |
João Cavaleiro Rufo1,2,3, Inês Paciência1,2,3, Diana Silva1, Carla Martins1, Joana Madureira2, Eduardo de Oliveira Fernandes2, Patrícia Padrão4, Pedro Moreira4, Luís Delgado1, André Moreira1,3,4.
Abstract
BACKGROUND: Endurance swimming exercises coupled to disinfection by-products exposure has been associated with increased airways dysfunction and neurogenic inflammation in elite swimmers. However, the impact of swimming pool exposure at a recreational level on autonomic activity has never been explored. Therefore, this study aimed to investigate how swimming pool attendance is influencing lung and autonomic function in school-aged children.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29529048 PMCID: PMC5846785 DOI: 10.1371/journal.pone.0193848
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow chart of the recruited participants.
Round-edged boxes represent the questions that allowed classification of participants into three different groups according to the respective answers: current, past and non-swimmers.
Characteristics of the participants.
| Current swimmers | Past swimmers | Non-swimmers | ||
|---|---|---|---|---|
| 205 (99) | 228 (115) | 342 (175) | ||
| 8.7 ±0.8 | 8.6 ±0.7 | 8.9 ±0.8 | ||
| 30.9 (26.6 to 36.9) | 32.1 (28.2 to 37.8) | 30.8 (26.9 to 37.3) | ||
| 135 (130 to 139) | 136 (131 to 141) | 136 (131 to 141) | 0.196 | |
| 100.0 | 98.3 | 98.2 | 0.965 | |
| FVC (L) | 1.88 (1.71 to 2.15) | 1.91 (1.71 to 2.18) | 1.88 (1.66 to 2.10) | 0.125 |
| FEV1 (L) | 1.73 (1.58 to 1.95) | 1.78 (1.60 to 1.99) | 1.74 (1.55 to 1.92) | 0.081 |
| FEV1/FVC (%) | 92.8 (89.1 to 96.1) | 92.5 (89.0 to 96.6) | 92.7 (88.8 to 96.4) | 0.998 |
| FEF25-75 (L/s) | 2.23 (1.97 to 2.71) | 2.36 (1.93 to 2.71) | 2.27 (1.91 to 2.59) | 0.423 |
| PEF (L/s) | 3.77 (3.30 to 4.38) | 3.77 (3.38 to 4.21) | 3.69 (3.27 to 4.27) | 0.641 |
| 70 (20 to 130) | 60 (10 to 120) | 60 (-10 to 110) | ||
| 4.0 (1.3 to 7.2) | 3.4 (0.6 to 6.7) | 3.1 (-0.7 to 6.2) | ||
| 40 (-30 to 100) | 30 (-30 to 80) | 20 (-40 to 90) | 0.219 | |
| 12 (7 to 20) | 11 (6 to 20) | 10 (5 to 19) | 0.086 | |
| Clinical criteria (n, %) | 11.7% | 8.3% | 9.4% | 0.459* |
| Functional criteria (n, %) | 6.3% | 7.0% | 6.4% | 0.957* |
| Treated asthma (n, %) | 6.3% | 4.0% | 6.1% | 0.441* |
| Ever asthma (n, %) | 7.3% | 4.8% | 7.3% | 0.438* |
| 66.7% | 62.9% | 54.4% | 0.465* | |
| 33.3% | 33.8% | 31.1% | 0.907* | |
| 32.8 | 39.5 | 34.2 | 0.302* | |
| 27.0% | 21.0% | 32.4% | ||
| Maximum (mm, mean ± sd) | 5.2 ±0.9 | 5.3 ±1.0 | 5.3 ±0.8 | 0.278¥ |
| Minimum (mm, mean ± sd) | 3.4 ±0.6 | 3.4 ± 0.6 | 3.4 ±0.6 | 0.537¥ |
| CON (%, mean ± sd) | 35 ±5 | 36 ±5 | 36 ±5 | 0.203¥ |
| ACV (mm/s, mean ± sd) | 3.8 ±0.7 | 3.9 ±0.8 | 4.0 ±0.7 | |
| MCV (mm/s, mean ± sd) | 5.1 ±1.0 | 5.3 ±1.0 | 5.4 ±0.9 | |
| ADV (mm/s, mean ± sd) | 1.2 ±0.3 | 1.2 ±0.4 | 1.2 ±0.3 | 0.709¥ |
| T75 (s, mean ± sd) | 1.7 ±0.7 | 1.7 ±0.7 | 1.7 ±0.7 | 0.987¥ |
Data reported as median (P25 to P75) unless otherwise stated. BMI: body mass index; FEV1: forced expiratory volume in the first second of FVC; PEF: Peek expiratory flow; FVC: forced vital capacity; FEF25-75: forced expiratory flow middle portion of FVC; EBC: exhaled breath condensate; CON: percentage of pupil constriction; ACV: average constriction velocity; MCV: maximum conscription velocity; ADV: average dilation velocity. The p values signalling differences between the three groups were calculated using the Kruskal-Wallis test for non-parametric variables, with the exception of cases marked with (*) which were calculated using qui-square tests, and (¥), which were calculated using one-way ANOVA (for normal distributions).
βThe following operational asthma definitions were adopted: i) Clinical criteria–at least a 12% increase in FEV1 after bronchodilation and over 200mL and/or asthma diagnosed by a physician with reported symptoms (wheezing, dyspnoea or dry cough) occurring in the past 12 months; ii) Functional criteria–at least a 12% increase in FEV1 after bronchodilation and over 200mL; iii) Treated asthma criteria–asthma diagnosed by a physician and currently under inhaled corticosteroid treatment; and iv) Ever asthma–asthma diagnosed by a physician.
Fig 2Median (with 25 and 75 percentiles) levels of exhaled NO and FEV1 reversibility, and mean ±SD of measured average constriction velocity (ACV) and maximum constriction velocity (MCV) among the three groups.
CS–current swimmers; PS–past swimmers; NS–non-swimmers. *Represents significant differences between two groups indicated by the extremities of the horizontal line (p<0.05).
Spearman’s correlation test between continuous clinical parameters and the number of years in swimming practice.
Values represent the Spearman’s correlation coefficient. Significant correlations are expressed in bold.
| Number of years in swimming practice (rho) | |
|---|---|
| FVC | .098 |
| FEV1 | |
| FEV1/FVC | -.001 |
| FEF 25–75% | .054 |
| PEF | |
| Forced expiratory flow | .008 |
| FEV1 reversibility | .064 |
| .016 | |
| Maximum diameter | .014 |
| Minimum diameter | -.030 |
| CON | |
| ACV | .013 |
| MCV | -.001 |
| ADV | |
| T75 |
Fig 3Risk analysis of early swimming (children who started swimming before the age of 3) in the development of allergic diseases and asthma.
Results are represented as OR (5–95%CI).
Fig 4Logistic regression between the number of years in swimming practice and the assessed clinical outcomes (adjusted for age and “early swimming”).
Participants were stratified according to their atopic status: A) Atopic children; and B) Non-atopic children. Results are represented as β (5–95%CI). *There were no non-atopic children reporting symptoms of allergic rhinitis.